Drug Profile
Research programme: anti-HIV microbicides - GlaxoSmithKline/IPM
Alternative Names: Anti-HIV microbicides research programme - GlaxoSmithKline/IPMLatest Information Update: 13 Mar 2008
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer GlaxoSmithKline; International Partnership for Microbicides
- Class
- Mechanism of Action Virus internalisation inhibitors; Virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported HIV infections
Most Recent Events
- 13 Mar 2008 No development reported - Preclinical for HIV infections in USA (Vaginal)
- 12 Oct 2004 Preclinical trials in HIV infections prevention in USA (Vaginal)